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Objective: Repetitive transcranial magnetic stimulation (rTMS) to the temporoparietal region has been pro-
posed as a therapeutic option for auditory verbal hallucinations (AVH). However, most large randomized
controlled trials failed to demonstrate a superior effect of rTMS treatment as compared to sham. Previous
studies applied daily rTMS sessions for one or more weeks to summate its effects. However, the effect of a
single rTMS treatment on AVH-severity has never been studied, making it unclear if there is an initial effect
that could be increased by repeated treatment.
Methods: In three separate sessions, twenty-four patients with a psychotic disorder received 1-Hz rTMS to
the left temporoparietal cortex, its right-sided homologue or a centro-occipital control site. Severity of
AVH was assessed before and after each rTMS session and resting-state EEGs were recorded to investigate
the neuronal effects of rTMS.
Results: Stimulation of the temporoparietal cortices was not more effective in reducing AVH-severity
than control-site stimulation. In addition, EEG-related power and connectivity measures were not affected
differently across stimulation sites and changes in neuronal activity did not correlate with changes in AVH-
severity.
Conclusions: These results may suggest a placebo effect of a single session of 1-Hz rTMS treatment on AVH-
severity.© 2012 Elsevier B.V. Open access under the Elsevier OA license. 1. Introduction
Auditory verbal hallucinations (AVH) are one of the core symp-
toms of schizophrenia (Nayani and David, 1996). About one-fourth
of patients have AVH that are refractory to antipsychotic medication
(Shergill et al., 1998). Medication-resistant AVH can lead to severely
disrupted social functioning and increased risk for suicide (Falloon
and Talbot, 1981; Cheung et al., 1997). For this group, low-
frequency repetitive transcranial magnetic stimulation (rTMS), a
non-invasive method that uses magnetic pulses to alter brain activity,
appears to be a promising treatment option (Hoffman et al., 1999;
reviewed by Slotema et al., 2010b). However, the exact mechanism
by which low-frequency rTMS may improve AVH remains elusive.
When low-frequency rTMS (±1-Hz) is applied over the scalp for at
least 15 min, cortical activity at the targeted region is reduced for anter Utrecht; Department of
ht; The Netherlands. Tel.: +31
an Lutterveld).
vier OA license. short duration of time (Chen et al., 1997). When stimulation with
rTMS is applied repeatedly, the targeted area is thought to become
less active for a longer period. This effect may be comparable to
Long-Term Depression (LTD) as observed in single-cell recordings
after prolonged stimulation (Christie et al., 1994; Hoffman and
Cavus, 2002). For the treatment of AVH, low-frequency rTMS is usual-
ly repeated for several consecutive days, typically daily for 1–3 weeks
(Hoffman et al., 1999; Fitzgerald et al., 2005; Slotema et al., 2010a).
Initial randomized-controlled trials (RCTs) have shown a remark-
able efﬁcacy of rTMS in reducing AVH as compared to an inactive pla-
cebo condition (Hoffman et al., 2000, 2003; Chibbaro et al., 2005;
Hoffman et al., 2005; Poulet et al., 2005; Brunelin et al., 2006),
which was summarized in several meta-analyses (Aleman et al.,
2007; Tranulis et al., 2008; Freitas et al., 2009; Slotema et al.,
2010b). However, several large RCTs published after these meta-
analyses failed to ﬁnd a signiﬁcant difference between real and
sham-rTMS (Vercammen et al., 2009; Loo et al., 2010; Slotema et al.,
2010a). These recent studies suggest that 1-Hz stimulation may not
be effective. It remains unclear whether this lack in effect is caused
by a fundamental inability of 1-Hz TMS to affect cerebral areas that
are crucially involved in AVH, or, alternatively, if there is an initial
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or twice daily repetition. This study aims to further explore the neu-
ronal mechanisms underlying the rTMS effect on AVH by investigat-
ing the acute effects of 1-Hz rTMS on AVH-severity and on resting-
state electroencephalography (EEG). If a single low-frequency rTMS
session can be demonstrated to affect AVH, we expect to ﬁnd larger
decreases in AVH-severity when rTMS is applied to the temporoparie-
tal cortex compared to rTMS at a control area. In addition, decreases
in AVH-severity due to rTMS are expected to be associated with




Thirty-two schizophrenia-spectrum patients experiencing fre-
quent auditory verbal hallucinations (AVH) were recruited at the Uni-
versity Medical Center in Utrecht in The Netherlands. Patients were
diagnosed using the Comprehensive Assessment of Symptoms and
History (CASH) interview (Andreasen et al., 1992) according to
DSM-IV criteria by an independent psychiatrist. The main inclusion
criteria were: AVH more frequently than once per hour and
treatment-resistance for at least two antipsychotic agents, adminis-
tered at adequate dosages and for at least six weeks (Hoffman et al.,
2003). Antipsychotic and other psychotropic medication were stable
for at least three weeks before entering the study and were kept sta-
ble during the three weeks of participation. Exclusion criteria were:
history of epilepsy, a ﬁrst-degree relative with epilepsy, head trauma
or other cerebral pathology, metal objects inside or around the body
that could not be removed, pregnancy, use of benzodiazepines or
anti-epileptics, and alcohol use of more than three units per day.
Eight out of thirty-two patients were excluded from analysis (1
patient did not experience AVH during the experimental sessions, 2
patients did not close their eyes during EEG acquisition, from 4 pa-
tients no full datasets were available, and 1 patient had trouble an-
swering the questions in the AVH-related questionnaires). Mean age
of the remaining 24 patients (17 male, 7 female) included in the anal-
ysis was 41 yrs (SD 14, range: 19–59). Demographic and clinical char-
acteristics of participants are presented in Table 1. All patients gave
their written informed consent and the study was approved by the
ethics committee of the University Medical Center in Utrecht.
2.2. Study protocol
Patients received rTMS on three separate occasions on either the
left temporoparietal cortex (i.e. midway between the T3 and P3
sites according to the international 10/20 system of EEG electrode
placement (Jasper, 1958), the right temporoparietal cortex (i.e.





Diagnosis Psychosis NOS (5); Katatonic
schizophrenia (1); Paranoid schizophrenia
(14); Disorganized schizophrenia
(1); Schizo-affective (3)
Age of onset AVHa 20 (12)
Antipsychotic medication Atypical (21); Typical (2); Both (1)
a Data reported as±standard deviation. NOS = not otherwise speciﬁed. AVH = au-
ditory verbal hallucinations.Oz position). As the V1 area of the visual cortex is neither involved
in auditory language processing nor in the generation of AVH
(Silbersweig et al., 1995; Kandel et al., 2000; Copolov et al., 2003;
Jardri et al., 2010; Kuhn and Gallinat, 2011), and in a pilot experiment
subjects reported similar scalp sensations during rTMS directed at
this area as to left and right temporoparietal cortex stimulation, the
centro-occipital cortex was chosen as an active control site. Stimula-
tion of the three sites was interspersed with a week, and stimulation
for each patient took place on the same time of day. To avoid bias in
allocating patients to one of the six possible sequences of stimulation,
patients were enrolled in each arm of the experiment by order of par-
ticipation (i.e. patient 1 in arm 1, patient 2 in arm 2, etc., patient 7 in
arm 1, patient 8 in arm 2 etc.). The design of the study was counter-
balanced, i.e. each arm of the six sequences of stimulation was ﬁlled
by four patients. To investigate whether patients saw phosphenes
during occipital cortex stimulation, participants were asked whether
they saw anything unusual during stimulation. This question was
also asked after left and right temporoparietal cortex stimulation.
After the last session, patients were asked to rank their physical sen-
sations during rTMS treatment over the three rTMS sessions.
2.3. rTMS
A 70-mm air-cooled ﬁgure-of-eight coil (Magstim Company Ltd.,
Whitland, UK) was used for rTMS treatment at 90% of the individual
motor threshold (MT). Each individual's motor threshold was
assessed by determining the lowest stimulation intensity at which
an observable hand movement contralateral to the stimulated hemi-
sphere could be elicited in ﬁve out of ten TMS administrations
(Schutter and van Honk, 2006). The MT for occipital stimulation
was 90% of the average of the MTs of the left and right hemisphere.
Patients received stimulation for 20 min at 1-Hz. During treatment
patients sat in a comfortable chair while their head and the TMS coil
were ﬁxated. All participants wore sound attenuating earplugs during
the study to prevent hearing damage.
2.4. Patient assessments
Before and after each treatment with rTMS, AVH-severity was
assessed using three paradigms (Fig. 1). First, patients indicated the
presence of AVH by button-press for 10 min. The length of all AVH ep-
isodes was added up to calculate total AVH duration in this time-
frame. After this, a baseline score regarding AVH-severity during the
button-press paradigm was set using the Hallucination Change Scale
(HCS) (Hoffman et al., 2003). The HCS is an indication of the general
severity of AVH as experienced by the patient. Pre-rTMS HCS scores
were always assigned a score of 10. Subsequently, AVH-severity dur-
ing the button-press paradigm was also assessed using the Auditory
Hallucinations Rating Scale (AHRS). The AHRS is a questionnaire
assessing multiple characteristics of AVH such as the frequency of oc-
currence, loudness of voices, length of AVH, inﬂuence and discomfort
of AVH as experienced by the patient (Hoffman et al., 2003).
After rTMS treatment, patients again performed the button-
press experiment for 10 min. After this they indicated the change
in AVH-severity relative to the pre-rTMS HCS score of 10 on a
scale from 0 to 20. A score of 0 indicated total absence of AVH,
while a score of 20 indicated twice the severity of AVH compared
to baseline. Subsequently AVH-severity was again assessed using
the AHRS.
2.5. Electrophysiological recordings
After baseline patient assessments (AVH duration, HCS and AHRS),
and preceding rTMS stimulation, resting-state eyes-closed electroen-
cephalography (EEG) data were recorded for ﬁve minutes. The proce-
dure was repeated after rTMS stimulation (Fig. 1). Data acquisition
Fig. 1. Outline of the experimental procedure. AVH = auditory verbal hallucination, HCS = hallucination change scale, AHRS = auditory hallucinations rating scale, EEG =
electroencephalography.
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lands) using a cap with 64 Active Two electrodes, arranged according
to the 10–20 system. Signals were digitized on-line by a computer at a
rate of 2048 Hz.
2.6. Data analysis
Detailed information regarding EEG power and graph analysis is
provided in Supplementary data S1.
2.7. Statistical analyses
All statistical analyses were performed with SPSS (version 15.0).
The Greenhouse–Geisser correction was used to adjust the degrees
of freedom when the assumption of sphericity was violated in
repeated-measures Analysis Of Variance (ANOVA). Pair-wise tests of
non-normally distributed data were conducted by Wilcoxon-rank
tests instead of paired t-tests. Correlation analyses were conducted
using Pearson's correlation coefﬁcient for normally distributed data;
otherwise Kendall's tau was used.
2.7.1. Scalp sensations
Scalp sensations across rTMS target sites were analyzed using
Friedman's ANOVA.
2.7.2. Patient assessments
The effects of 1-Hz rTMS on AVH duration, HCS score, and AHRS
score were analyzed through repeated-measures ANOVA with
within-subject factors ‘target site’ (left temporoparietal cortex, right
temporoparietal cortex and occipital cortex) and ‘treatment’ (pre-
rTMS and post-rTMS). Post-hoc paired t-tests were used to examine
signiﬁcant interaction effects, with correction for multiple compari-
sons using false discovery rate (FDR) correction (Benjamini and
Hochberg, 1995).
2.7.3. Electrophysiology
Detailed information regarding statistical testing of EEG power
and graph analysis is provided in Supplementary data S2.
3. Results
3.1. rTMS
The treatment was tolerated well by all patients, and no patients
experienced phosphenes during rTMS.
3.2. Scalp sensations
Friedman's ANOVA did not reveal any signiﬁcant differences in
scalp sensations across rTMS target-sites [Chi-square=2.95; df=2;
P=0.23].3.3. Patient assessments
Repeated-measures ANOVAs revealed signiﬁcant main effects of
treatment on AVH duration [F(1,23)=7.187; P=0.013], HCS score
[F(1,23)=13.718; P=0.001], and AHRS score [F(1,23)=10.218;
P=0.004], indicating lower AVH-severity after rTMS. A treatment×
location interaction effect was found for HCS score [F(1,23)=3.622;
P=0.035]. Post-hoc testing revealed a signiﬁcant difference after
left temporoparietal rTMS and occipital rTMS [t(23)=−2.300;
P=0.0465], indicating lower HCS score decrease after left temporo-
parietal rTMS compared to occipital rTMS. Fig. 2 shows average pre-
rTMS and post-rTMS AVH duration, HCS scores, and AHRS scores.
3.4. Electrophysiology
3.4.1. Absolute power
Repeated-measures ANOVA revealed signiﬁcant main effects of
treatment on whole-head theta-band power [F(1,23)=10.998;
P=0.003] and alpha-band power [F(1,23)=6.795; P=0.016], indi-
cating signiﬁcant increases in whole-head theta band and alpha-
band power after rTMS treatment. No signiﬁcant main effect
was found for the beta band. A treatment×location interaction
effect was found for whole-head alpha-band absolute power
[F(1,23)=3.816; P=0.044]. Post-hoc testing with false discovery
rate (FDR) correction did however not reveal any signiﬁcant differ-
ences. Repeated-measures ANOVAs investigating the local effect of
rTMS revealed no signiﬁcant three-way interactions for all three fre-
quency bands, indicating that rTMS treatment did not lead to different
changes in power at the brain area underlying the target site com-
pared to the two non-used target sites across the three stimulation
sessions.
3.4.2. Network characteristics
Repeated-measures ANOVA revealed signiﬁcant main effects of
treatment for the clustering coefﬁcient (C) in the alpha-band
[F(1,23)=4.400; P=0.047], indicating a decrease in clustering after
rTMS. For small-worldness (C/L), signiﬁcant main effects of treatment
were found in the theta band [F(1,23)=9.212; P=0.006] and beta
band [F(1,23)=4.727; P=0.040], indicating decreases after rTMS in
these frequency bands. No treatment×location interaction effects
were observed.
Detailed information for all dependent variables including means
and standard deviations are provided in Supplementary data S3.
3.5. Correlation analysis
3.5.1. Power
No signiﬁcant correlations were found between changes in whole-
head theta-band power for each stimulation session and changes in
AVH duration, HCS, or AHRS measures. Also no signiﬁcant correla-
tions were found between changes in whole-head alpha-band
power and changes in AVH duration, HCS, or AHRS scores.
Fig. 2. Average effect of rTMS on Auditory Hallucination Rating Scale (AHRS), Hallucination Change Scale (HCS), and AVH duration. TPC: temporoparietal cortex. Error bars indicate
standard error of the mean (SEM).
177R. van Lutterveld et al. / Schizophrenia Research 137 (2012) 174–1793.5.2. Network characteristics
A signiﬁcant correlation between a change in clustering coefﬁcient
in the alpha band after left temporoparietal rTMS was found with
AVH duration [r=0.671; P=0.005]. This effect was carried by an out-
lier (on both clustering coefﬁcient and AVH duration). Removal of the
outlier led to an insigniﬁcant outcome.
4. Discussion
This is the ﬁrst study to investigate the acute effect of repetitive tran-
scranial magnetic stimulation (rTMS) on auditory verbal hallucinations
(AVH). Application of rTMS to the left temporoparietal cortex, right
temporoparietal cortex, and the occipital control site all signiﬁcantly de-
creased AVH-severity asmeasured by hallucination duration, the Hallu-
cination Change Scale (HCS), and the Auditory Hallucinations Rating
Scale (AHRS). For the HCS, stimulation of the left temporoparietal cor-
tex was less effective in reducing AVH-severity than stimulation of the
control site. This effect could not be observed on the duration of hallu-
cinations and on the AHRS. The general observation was that stimula-
tion at therapeutic locations and at the control site all led to symptom
decrease, without much difference between the three locations.
Electroencephalography (EEG) recording before and after rTMS
treatment revealed that rTMS therapy increased whole-head theta-
band power, alpha-band power, and decreased ‘small-worldness’ in
the theta and beta bands. In addition, a decrease in alpha-band clus-
tering coefﬁcient was observed. These overall changes did not corre-
late with changes in AVH-severity. Also, no differential effect of rTMS
target-site was found on whole-head, local, and network-based EEG
measures. Similar to the clinical effects, we found neuronal responses
to all three locations, without a difference between therapeutic and
control sites.
It is currently unclear if 1-Hz rTMS can be used effectively to treat
AVH. Since 25% of schizophrenia patients with AVH are medication-
resistant, an alternative treatment is most welcome. However, if wewish to apply rTMS for AVH, we need to obtain more information
about the neuronal mechanisms by which rTMSmay affect this symp-
tom. We showed that a single rTMS-session to therapeutic locations
was not superior to control-site stimulation. These ﬁndings may sug-
gest a placebo effect of 1-Hz rTMS on AVH-severity, possibly through
scalp sensations, or relaxation during treatment associated with rTMS
stimulation. The absence of any correlations between improvements
in AVH-severity and changes in neuronal activity could be seen as in
line with this interpretation.
The fact that several randomized controlled trials did observe an
effect on AVH-severity through repeatedly stimulating the left tem-
poroparietal cortex with 1-Hz rTMS may be explained by their inac-
tive sham condition (Hoffman et al., 1999, 2000; Chibbaro et al.,
2005; Hoffman et al., 2005; Poulet et al., 2005; Brunelin et al.,
2006). In these studies sham rTMS was applied using a placebo coil
or by tilting the rTMS coil by 45°. While these sham conditions pro-
duce some acoustic stimulation, scalp sensations are absent or greatly
diminished (Aleman et al., 2007). As such, patients who experience
stronger scalp sensations during real rTMSmay feel they are receiving
more powerful treatment. Indeed, placebo effects have been shown to
be greatly enhanced in case of suggestion of stronger treatment, as for
example ingestion of two placebo pills elicits stronger effects than in-
gestion of only one, and injection of placebo is more powerful than
oral administration (Blackwell et al., 1972; de Craen et al., 2000). In
this study, stimulation of the control site produced similar scalp sen-
sations as stimulation of the temporoparietal sites, thereby control-
ling for these effects.
However, an important alternative explanation regarding the in-
terpretation of the present results as a placebo effect concerns the
possible remote effects of rTMS. RTMS is able to inﬂuence brain ac-
tivity in regions distant from the stimulated brain region through
neuronal connections (Horacek et al., 2007). The power, clustering,
path length, and small-worldness measures in the various frequency
bands may not have been sensitive enough to pick up these signals.
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site stimulation affected brain activity in regions associated with au-
ditory verbal hallucinations through intra-hemispheric connections.
The same line of reasoning goes for the absence of signiﬁcant corre-
lations with measures of AVH severity. Perhaps spatial and temporal
analyses in source space may provide more sensitivity to establish
signiﬁcant differences across conditions as well as correlations with
AVH severity. Neuroimaging methods with a high spatial resolution,
such as functional magnetic resonance imaging (fMRI) may be espe-
cially suitable to investigate this issue and give a more deﬁnite an-
swer on the matter.
4.1. Limitations
In this study no differential effect of rTMS target site was observed
on EEG measures. It can however not be excluded that rTMS applied
to the temporoparietal and occipital cortex leads to a generalized ef-
fect on EEG-based power and network characteristics instead of to
local effects. However, two studies investigated the effect of 1-Hz
rTMS on EEG spectral power during rest, and did observe differential
effects of rTMS on brain regions instead of a generalized effect
(Schutter et al., 2001; Brignani et al., 2008). Lastly, the present
study investigated the acute effects of rTMS, and was as such unable
to detect any delayed effects. However, most larger RCTs failed to
ﬁnd a difference between real and sham rTMS, suggesting that there
are no delayed effects of rTMS on AVH symptomatology (Fitzgerald
et al., 2005; Vercammen et al., 2009; Loo et al., 2010; Slotema et al.,
2010a).
In sum, this is the ﬁrst placebo-site controlled study assessing
both clinical and neuronal effects of rTMS on AVH. Stimulation of
the temporoparietal cortices was not more effective in reducing
AVH symptoms than control-site stimulation. Moreover, electrophys-
iological measures were not affected differently by rTMS at therapeu-
tic sites as compared to control-site stimulation. These results imply
that a single session of 1-Hz rTMS applied to the temporoparietal re-
gion does not improve AVH better than occipital cortex stimulation
and may suggest a placebo effect of 1-Hz rTMS on AVH-severity.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.schres.2012.01.010.
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